{
 "query": "tildrakizumab",
 "ingredient": "tildrakizumab",
 "slug": "tildrakizumab",
 "rxcui": "2053436",
 "brands": [],
 "names": [
  "tildrakizumab"
 ],
 "classes": [
  {
   "id": "L04AC",
   "name": "Interleukin inhibitors"
  }
 ],
 "alternatives": [
  "anakinra",
  "basiliximab",
  "bimekizumab",
  "brodalumab",
  "canakinumab",
  "daclizumab",
  "guselkumab",
  "ixekizumab",
  "mirikizumab",
  "rilonacept",
  "risankizumab",
  "sarilumab",
  "satralizumab",
  "secukinumab",
  "siltuximab",
  "spesolimab",
  "tocilizumab",
  "ustekinumab"
 ],
 "label": {},
 "faers": {
  "total": 1066,
  "serious": 993,
  "death": 112,
  "hospitalization": 482,
  "primary_suspect": 1066,
  "top_reactions": [
   [
    "Drug Ineffective",
    66
   ],
   [
    "Death",
    63
   ],
   [
    "Psoriasis",
    51
   ],
   [
    "Pneumonia",
    44
   ],
   [
    "Urinary Tract Infection",
    39
   ],
   [
    "Off Label Use",
    36
   ],
   [
    "Product Dose Omission Issue",
    35
   ],
   [
    "Condition Aggravated",
    30
   ],
   [
    "Covid-19",
    30
   ],
   [
    "Intentional Dose Omission",
    30
   ],
   [
    "Fatigue",
    23
   ],
   [
    "Treatment Failure",
    23
   ],
   [
    "Cerebrovascular Accident",
    22
   ],
   [
    "Myocardial Infarction",
    22
   ],
   [
    "Fall",
    21
   ]
  ],
  "by_year": {
   "2019": 25,
   "2020": 68,
   "2021": 74,
   "2022": 101,
   "2023": 193,
   "2024": 240,
   "2025": 237,
   "2026": 111
  },
  "by_year_primary": {
   "2019": 25,
   "2020": 68,
   "2021": 74,
   "2022": 101,
   "2023": 193,
   "2024": 240,
   "2025": 237,
   "2026": 111
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 0,
  "nda": 0,
  "anda": 0,
  "first_approval": "",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [],
  "unapproved": false,
  "first_approval_fmt": ""
 },
 "trials": {
  "total": 44,
  "completed": 22,
  "terminated": 4,
  "with_results": 13,
  "industry": 31,
  "phase3": 12,
  "results_share": 0.5909090909090909,
  "terminated_share": 0.09090909090909091
 },
 "pubmed": {
  "rct": 23,
  "meta": 3,
  "recent_rct": 15,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 0.0,
  "records": 0,
  "by_name": [],
  "names_checked": [
   "tildrakizumab"
  ],
  "source": "bulk-index"
 },
 "partd": null,
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": null,
 "scores": {
  "safety": {
   "score": 100,
   "letter": "A",
   "why": [
    "Death share in reports is near or below the FAERS average (1.2x)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 33,
   "letter": "F",
   "why": [
    "23 randomized trials and 3 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)",
    "'Drug ineffective' is the single most-reported item about this drug in FAERS (-5)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 100,
   "letter": "A",
   "why": [
    "No recalls on record since 2016"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 100,
   "letter": "A",
   "why": [
    "Pharma paid doctors $0 tied to this drug last year: negligible",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "18 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 80,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are death, psoriasis, pneumonia. How would we recognize and handle those?",
  "Off-label use is among the most-reported items for this drug. Is my use on-label, and if not, what evidence supports it?",
  "Why this one over anakinra, basiliximab, bimekizumab? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}